Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Open-Label PK and Safety Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infection
2016-002345-39Phase 2
- Sponsor
- Gilead Sciences
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bictegravir + emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1 and human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by Gilead Sciences.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2016-002345-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002345-39.